Latest News for: esmo
Edit
Rio Grande Sun
12 Dec 2025
HanchorBio Announces Oral Presentation of HCB101 at the ESMO Immuno-Oncology Congress 2025
International debut underscores emerging role for macrophage checkpoint therapy in gastric cancer, triple-negative breast cancer, and other hard-to-treat solid tumors ... .
Edit
BeyondSpring Announces ESMO Asia Presentation on Plinabulin + Docetaxel Improving Survival in Large Phase 3 ...
Nasdaq Globe Newswire 12 Dec 2025
FLORHAM PARK, N.J., Dec ... (NASDAQ ... Baohui Han of Shanghai Chest Hospital at the European Society for Medical Oncology (ESMO) Asia Congress 2025. .
Edit
Purple Biotech Reports Positive New Preclinical Data at ESMO Immuno-Oncology Congress 2025 (Purple Biotech Ltd)
Public Technologies 11 Dec 2025
) פרפל ביוטק בע"מ. PURPLE BIOTECH LTD. Corporation no. 520031238. Israel Securities Authority Tel Aviv Stock Exchange C002( Public) Reported via MAGNA. 11/12/2025. www.isa.gov.il www.tase.co.il Reference. 2025-02-098855. Immediate Report ... 06/08/2024.
Edit
Purple Biotech Reports Positive New Preclinical Data Demonstrating Multi-Arm Anti-Tumor Activity Across Two CAPTN-3 Tri-Specific Antibodies at ESMO Immuno-Oncology Congress 2025 (Form 6-K) (Purple Biotech Ltd)
Public Technologies 11 Dec 2025
Edit
Updated Efficacy Data of Ivonescimab Combined with Chemotherapy as First-Line Treatment for TNBC Presented at ESMO IO 2025
PR Newswire 11 Dec 2025
Preliminary results from this study were previously announced at the European Society for Medical Oncology (ESMO) Congress 2024 and the 2024 San Antonio Breast Cancer Symposium (SABCS).
Edit
ESMO ASIA | HANSOH PHARMA ANNOUNCES RESULTS OF RESENCATINIB (HS-10365，A HIGHLY SELECTIVE RET INHIBITOR）FOR THE TREATMENT OF PATIENTS WITH RET-FUSION LOCALLY ADVANCED OR METASTATIC NSCLC (Hansoh Pharmaceutical Group Co Ltd)
Public Technologies 11 Dec 2025
Edit
Biohaven Presents Clinical Safety and Efficacy Data for BHV-1510, a Next-Generation Trop2 Antibody Drug Conjugate in Combination with Cemiplimab at the 2025 European Society for Medical Oncology (ESMO) Immuno-Oncology Congress
PR Newswire 11 Dec 2025
BHVN) announced today that it presented clinical safety and efficacy data for BHV-1510 at the 2025 European Society for Medical Oncology (ESMO) Immuno-Oncology Congress, taking place from December 10-12, 2025, in London, United Kingdom ... Figure 1 ... 2) ... .
Edit
Immatics Presents IMA203CD8 PRAME Cell Therapy Data from Ongoing Dose Escalation and Shows Promising Initial Anti-tumor Activity in PRAME-Positive Tumors at ESMO-IO 2025 Congress (Form 6-K) (Immatics NV)
Public Technologies 11 Dec 2025
Edit
Medicenna Updates MDNA11 Clinical Trial Results at the ESMO-IO Congress 2025, Further Bolstering its Anti-Tumor Activity in Advanced Solid Tumors (Medicenna Therapeutics Corp)
Public Technologies 10 Dec 2025
). The text version of this document is not available ... Disclaimer ... (noodl. 128308708) .
Edit
Medicenna Updates MDNA11 Clinical Trial Results at the ESMO-IO Congress 2025, Further Bolstering its Anti-Tumor ...
Nasdaq Globe Newswire 10 Dec 2025
MDNA11 demonstrates durable anti-tumor activity in phase-2 ...
Edit
NovaBridge Presents Positive Ragistomig Phase 1 Dose Expansion Data at ESMO-IO
Nasdaq Globe Newswire 10 Dec 2025
Edit
The Eagle-Tribune
10 Dec 2025
Medicenna Updates MDNA11 Clinical Trial Results at the ESMO-IO Congress 2025, Further
MDNA11 demonstrates durable anti-tumor activity in phase-2 ...
Edit
NEC Presents Phase I Results for Personalized AI-Powered Oral Cancer Vaccine NECVAX-NEO1 at ESMO Immuno-Oncology Congress 2025 (NEC Corporation)
Public Technologies 10 Dec 2025
The findings are being presented in a poster at the ESMO Immuno-Oncology Congress in London, United Kingdom, from December 10 to 12, 2025 ... The safety run-in phase showed no treatment-related toxicities, allowing a dose increase ... Poster title ... Authors. D.
Edit
NEC Presents Phase I Results for Personalized AI-Powered Oral Cancer Vaccine NECVAX-NEO1 at ESMO Immuno-Oncology ...
JCN Newswire 10 Dec 2025
The findings are being presented in a poster at the ESMO Immuno-Oncology Congress in London, United Kingdom, from December 10 to 12, 2025 ... The safety run-in phase showed no treatment-related toxicities, allowing a dose increase ... Poster title ... Authors. D.
- 1
- 2
- Next page »